Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Microba Life Sciences Limited ( (AU:MAP) ) has provided an update.
Microba Life Sciences Limited announced a change in the director’s interest, specifically regarding Richard Bund’s holdings. The announcement detailed the lapse of 200,000 options and the on-market disposal of 1,829,460 ordinary shares, resulting in Bund holding 31,651,339 ordinary shares. This change reflects adjustments in the director’s investment portfolio, potentially impacting the company’s stock market activities and shareholder perceptions.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited operates in the life sciences industry, focusing on microbiome analysis and related technologies. The company provides services and products aimed at understanding and leveraging the human microbiome for health and wellness applications.
Average Trading Volume: 542,820
Technical Sentiment Signal: Sell
Current Market Cap: A$51.15M
For a thorough assessment of MAP stock, go to TipRanks’ Stock Analysis page.